ARN-24161

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameARN-24161
Drug Alias Namedopamine D3 receptor/GSK-3beta dual modulators (Heptares Therapeutics/Istituto Italiano di Tecnologia/University of Edinburgh/University of Bologna)dopamine D3 receptor/GSK-3beta dual modulators (Sosei Heptares/Istituto Italiano di Tecnologia/University of Edinburgh/University of Bologna)ARN-24161
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen synthase kinase-3 beta inhibitorsDopamine D3 receptor modulators
TargetsDopamine D3 receptorGlycogen synthase kinase-3 beta
Therapy Area/IndicationsBipolar Disorder
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItalyUnited KingdomJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNxera Pharma UK Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFondazione Istituto Italiano Di TecnologiaUniversity Of BolognaNxera Pharma UK Ltd +[5] 
Active IndicationsN/A
Inactive IndicationsBipolar Disorder

Other Information

ATC CodeN/A
Related LinksN/A